Free Trial

EyePoint Pharmaceuticals (EYPT) News Today

EyePoint Pharmaceuticals logo
$7.04 +1.08 (+18.12%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$7.35 +0.31 (+4.46%)
As of 09:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EYPT Latest News

EyePoint Pharmaceuticals, Inc. stock logo
Woodline Partners LP Buys 101,724 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Woodline Partners LP grew its stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 25.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 501,724 shares of the company's stock after acqui
EyePoint Pharmaceuticals, Inc. stock logo
Deutsche Bank AG Has $1.59 Million Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Deutsche Bank AG decreased its stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 67.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 213,382 shares of the company's stock after sell
EyePoint Pharmaceuticals, Inc. stock logo
BNP Paribas Financial Markets Purchases New Shares in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
BNP Paribas Financial Markets purchased a new stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 86,809 shares of the company's stock, valued at approxim
EyePoint Pharmaceuticals, Inc. stock logo
Northern Trust Corp Has $4.79 Million Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Northern Trust Corp lifted its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 36.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 643,157 shares of the company's stock after
EyePoint Pharmaceuticals, Inc. stock logo
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Purchased by Point72 Asset Management L.P.
Point72 Asset Management L.P. increased its position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 90.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 857,853 shares of the company's sto
EyePoint Pharmaceuticals, Inc. stock logo
What is HC Wainwright's Forecast for EYPT Q1 Earnings?
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Stock analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for EyePoint Pharmaceuticals in a research note issued to investors on Thursday, May 15th. HC Wainwright analyst Y. Chen anticipates that the compan
Q1 Earnings Forecast for EYPT Issued By HC Wainwright
EyePoint Pharmaceuticals, Inc. stock logo
Suvretta Capital Management LLC Acquires 1,607,268 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Suvretta Capital Management LLC boosted its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 31.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 6,783,091 shares of the company's stock afte
EyePoint Pharmaceuticals, Inc. stock logo
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Rating of "Buy" from Brokerages
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) has earned a consensus rating of "Buy" from the nine research firms that are currently covering the stock, Marketbeat reports. Nine analysts have rated the stock with a buy rating. The average 1 year price target among brokerages that
EyePoint Pharmaceuticals, Inc. stock logo
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Acquired by Cubist Systematic Strategies LLC
Cubist Systematic Strategies LLC raised its holdings in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 211.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 99,498 shares o
EyePoint Pharmaceuticals, Inc. stock logo
Patient Square Capital LP Has $10.51 Million Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Patient Square Capital LP boosted its stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 3.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,410,331 shares of the company's stock after purchasing
EyePoint Pharmaceuticals, Inc. stock logo
Balyasny Asset Management L.P. Raises Stock Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Balyasny Asset Management L.P. raised its stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 233.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 223,641 shares of the
EyePoint Pharmaceuticals, Inc. stock logo
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Sold by Laurion Capital Management LP
Laurion Capital Management LP lowered its stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 55.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 205,578 shares of the company's stock after selling 25
EyePoint Pharmaceuticals, Inc. stock logo
FY2025 EPS Estimates for EYPT Decreased by Cantor Fitzgerald
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Equities research analysts at Cantor Fitzgerald reduced their FY2025 EPS estimates for shares of EyePoint Pharmaceuticals in a research report issued on Thursday, May 8th. Cantor Fitzgerald analyst J. Kim now anticipates that the compan
EyePoint Pharmaceuticals, Inc. stock logo
Voya Investment Management LLC Purchases 57,205 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Voya Investment Management LLC raised its position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 342.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 73,914 shares of the company's stock af
EyePoint Pharmaceuticals, Inc. stock logo
Chardan Capital Has Lowered Expectations for EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price
Chardan Capital reduced their price objective on shares of EyePoint Pharmaceuticals from $33.00 to $27.00 and set a "buy" rating for the company in a research note on Thursday.
EyePoint Pharmaceuticals, Inc. stock logo
Alyeska Investment Group L.P. Buys 100,000 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Alyeska Investment Group L.P. grew its stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 39.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 351,348 shares of the company's stock after ac
EyePoint Pharmaceuticals, Inc. stock logo
Barclays PLC Has $895,000 Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Barclays PLC reduced its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 50.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 120,221 shares of the company's stock after selling 124,824 shares during
EyePoint Pharmaceuticals, Inc. stock logo
Susquehanna Fundamental Investments LLC Takes $922,000 Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Susquehanna Fundamental Investments LLC acquired a new position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 123,769 shares of the company's stock, valued at appr
EyePoint Pharmaceuticals, Inc. stock logo
EyePoint Pharmaceuticals (EYPT) Projected to Post Earnings on Wednesday
EyePoint Pharmaceuticals (NASDAQ:EYPT) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-7-eyepoint-pharmaceuticals-inc-stock/)
EyePoint Pharmaceuticals, Inc. stock logo
Ally Bridge Group NY LLC Makes New Investment in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Ally Bridge Group NY LLC acquired a new stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 348,000 shares of the company's stock, val
EyePoint Pharmaceuticals, Inc. stock logo
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Sold by Price T Rowe Associates Inc. MD
Price T Rowe Associates Inc. MD lowered its position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 13.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,144,747 shares of the
EyePoint Pharmaceuticals, Inc. stock logo
Oracle Investment Management Inc. Sells 350,000 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Oracle Investment Management Inc. lessened its stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 91.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 32,500 shares of the company's stock after selling 350,000 shares during
EyePoint Pharmaceuticals, Inc. stock logo
3,181,818 Shares in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Purchased by RA Capital Management L.P.
RA Capital Management L.P. bought a new stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 3,181,818 shares of the company's stock, valued at approximately $23,705
EyePoint Pharmaceuticals, Inc. stock logo
Renaissance Technologies LLC Reduces Stock Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Renaissance Technologies LLC lowered its position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 26.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 137,500 shares
EyePoint Pharmaceuticals, Inc. stock logo
TCG Crossover Management LLC Acquires 2,650,000 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
TCG Crossover Management LLC raised its stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 287.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,572,335 shares of the company's stock afte
EyePoint Pharmaceuticals, Inc. stock logo
Nantahala Capital Management LLC Buys New Shares in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Nantahala Capital Management LLC bought a new stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 600,000 shares of the company's stock, valued at appr
EyePoint Pharmaceuticals, Inc. stock logo
T. Rowe Price Investment Management Inc. Sells 1,061,815 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
T. Rowe Price Investment Management Inc. trimmed its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 83.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 206,939 shares of the company's stock after selling 1,061,815 s
EyePoint Pharmaceuticals, Inc. stock logo
Artia Global Partners LP Has $1.61 Million Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Artia Global Partners LP grew its position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 38.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 216,700 shares of the company's stock after purchasing an additional 60
EyePoint Pharmaceuticals, Inc. stock logo
Adage Capital Partners GP L.L.C. Boosts Stock Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Adage Capital Partners GP L.L.C. boosted its holdings in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 51.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,750,000 shares of
EyePoint Pharmaceuticals, Inc. stock logo
Blue Owl Capital Holdings LP Invests $4.97 Million in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Blue Owl Capital Holdings LP acquired a new position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 667,594 shares of the company's stock, valued at approximately $
EyePoint Pharmaceuticals, Inc. stock logo
Geode Capital Management LLC Has $11.47 Million Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Geode Capital Management LLC grew its position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 28.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,538,902 shares of the company's stock after purchasing an additiona
EyePoint Pharmaceuticals, Inc. stock logo
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Consensus Recommendation of "Buy" from Analysts
Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) have earned a consensus rating of "Buy" from the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. Nine research analysts have rated the stock with a buy rating. The average twelve-month pr
EyePoint Pharmaceuticals, Inc. stock logo
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) is Essex Woodlands Management Inc.'s 4th Largest Position
Essex Woodlands Management Inc. lessened its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 24.6% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,169,857 shares of the company's stock after selling 381,664 shares during
EyePoint Pharmaceuticals, Inc. stock logo
Vanguard Group Inc. Purchases 755,045 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Vanguard Group Inc. increased its position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 24.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,803,227 shares of the company's stock after acquir
EyePoint Pharmaceuticals, Inc. stock logo
Federated Hermes Inc. Increases Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Federated Hermes Inc. increased its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 92.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,707,445 shares of the company's stock after acquiring
EyePoint Pharmaceuticals, Inc. stock logo
Finepoint Capital LP Grows Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Finepoint Capital LP boosted its position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 57.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,111,104 shares of the company's stock a
Get EyePoint Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter.

EYPT Media Mentions By Week

EYPT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

EYPT
News Sentiment

1.27

0.87

Average
Medical
News Sentiment

EYPT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

EYPT Articles
This Week

8

4

EYPT Articles
Average Week

Get EyePoint Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:EYPT) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners